期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

囊泡单胺转运体在人胚胎脑组织中的分布特征及其与帕金森病的关系 被引量：2

Feature of distribution of vesicular monoamine transporter in human embryonic brain and their relationship with Parkinson's disease
下载PDF
导出
摘要 目的探讨囊泡单胺转运体(VMAT2)在人胚胎脑组织中的分布特征及其与帕金森病(PD)的关系。方法分别收集不同胎龄自然流产的新鲜胎儿脑组织,应用免疫组织化学方法和Western blot观察VMAT2和酪胺酸羟化酶(TH)在胎脑黑质致密部、腹侧被盖部和蓝斑分布的变化。结果免疫组织化学及Western blot显示,VMAT2在胎脑黑质致密部中的分布既少于腹侧被盖也少与蓝斑(均P<0.05)。结论胎脑VMAT2在黑质致密部中的分布少于腹侧被盖和蓝斑,黑质致密部保护作用薄弱可能是PD黑质多巴胺能神经元选择性受损的重要原因之一。 Objective To investigate the feature of distribution of vesicular monoamine transporter(VMAT2) in human embryonic brains and their relationships with Parkinson disease.Methods The distribution of VMAT2 and tyrosine hydroxylase (TH) in substantia nigra pars compacta(SNC), ventral tegmental ares(VTA) and locus coeruleus(LC) were examined by immunohistochemical staining and Western blot in human spontaneous abortion embryonic brains of different gestational age.Results The distribution of VMAT2 in SNc was less...
作者 田向阳 丁新生 闵敏 孙兴珍
机构地区 南京医科大学附属淮安第一医院神经内科 南京医科大学第一附属医院神经内科
出处 《临床神经病学杂志》 CAS 北大核心 2008年第4期270-272,共3页 Journal of Clinical Neurology
关键词 帕金森病 囊泡单胺转运体 免疫组织化学 酪胺酸羟化酶 人胚 Parkinson disease VMAT2 immunohistochemistry tyrosine hydroxylase human embryo
分类号 R742.5 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献7

  • 1叶民,丁新生,董海蓉,仇镇宁,管晓虹.转基因CHO细胞中VMAT_2抗毒性作用的研究[J].临床神经病学杂志,2002,15(2):69-72. 被引量：7
  • 2[2]Peter D,Jimenez J,Liu Y,et al.The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors[J].J Biol Chem,1994,269:7231.
  • 3[3]Speciale SG.MPTP insights into parkinsonian neurodegeneration[J].Neurotoxicol Teratol,2002,24:607.
  • 4[4]Liu YJ,Peter D,Roghani A,et al.A cDNA that suppresses MPP+ toxicity encodes a vesicular monoamine transporter[J].Cell,1992,70:539.
  • 5[5]Fumagalli F,Gainetdinov RR,Wang YM,et al.Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knockout mice[J].J Neurosci,1999,19:2424.
  • 6[6]Miller GW,Erickson JD,Perez JD,et al.Immunochemical analysis of vesicular monoamine transporter protein in Parkinson′s disease[J].Experimental Neurology,1999,156:138.
  • 7田向阳,丁新生,董海蓉.囊泡单胺转运体在帕金森病小鼠脑组织中的分布特征[J].南京医科大学学报（自然科学版）,2004,24(3):246-249. 被引量：4

二级参考文献21

  • 1[1]Timothy Denton,Bruce DH.A dopaminergic cell line variant resistant to the neurotoxin 1-Methyl-4-phenyl-1,2,3,6-Tetrahydropyridine.J Neurochem,1987,49:622
  • 2[2]Yongjian Liu,Doris Peter,Ali Roghani,et al.A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter.Cell,1992,21:539
  • 3[3]Yongjian Liu,Robert HE.The role of vesicular transport proteins in synaptic transmission and neural degeneration.Annu Rev Neurosci,1997,20:125
  • 4[4]Uhl GR.Hypothesis: The role of dopaminergic transporters in selective vulnerability of cells in parkinson's disease.Ann Rev Neurology,1998,43:555
  • 5[5]Trimbele WS,Linial M,Scheller RH.Celluar and molecular biology of the presynaptic nerve terminal.Annu Rev Neurosci,1991,14:93
  • 6[6]Hirsch EC.Mechanism and consequences of nerve cell death in Parkinson's disease.J Neural Transm Suppl,1999,56:127
  • 7[7]Masserana JM,Gong L,Kulaga H,et al.Dopamine induced apoptotic cell death of a catecholaminergic cell line derived from the central nervous system.Mol Parmacol,1996,50:1309
  • 8[8]Hurd Y,Pristupa Z,Herman M,et al.The dopamine transporter and dopamine D2 receptor mRNAs are differentially expressed in limbic-and motor-related subpopulation of human mesencephalic neurons.Neuroscience,1994,63:357
  • 9[9]Uhl GR,Walther D,Mash D,et al.Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons.Ann Neurol,1994,35:494
  • 10[10]Takahashi N,Uhl GR.Mouse synaptic vesicular monoamine transporter molecular cloning and genomic structure.Mol Rain Res,1997,49:7

共引文献9

同被引文献15

  • 1Kopin IJ, Markey SP. MPTP toxicity:implication for research in Parkinson's disease [ J ]. Annu Rev Neurosci, 1988,11:81 - 96.
  • 2Jakowec MW, Petzinger GM. 1 -methyl-d-phenyl-1,2,3,6-tetrahy- dropyridine lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates [ J ]. Comp Med, 2004,54 ( 5 ) : 497 -513.
  • 3Shimoji M ,Zhang L, Mandir AS ,et al. Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease[ J]. Brain Res Mol Brain Res,2005,134 (1) :103 -108.
  • 4Markey SP,Johannessen JN, Chiueh CC,et al. Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism [ J]. Nature, 1984,311:464 -467.
  • 5Staal RG, Sonsalla PK. Inhibition of brain vesicular monoamine transporter ( VMAT2 ) enhances 1-Methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata [ J ]. J Pharmacol Exp Ther, 2000,293:336 - 342.
  • 6Mitchell IJ,Lawson S, Moser B,et al. Glutamate-induced apoptosis results in a loss of striatal neurons in the Parkinsonian rat[ J]. Neuroscience, 1994,63 : 1 - 7.
  • 7Darcben F, Scherman, Henry JP. Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter[ J ]. Biochemistry, 1989,28 : 1692 - 1697.
  • 8Merickle A, Edwerd RH. Transport of histamine by Vesicular Monoamine Transporter-2 [ J ]. Neuropharmacol, 1995,34 : 1543 - 1547.
  • 9Buck K J, Amara SG. Chimeric dopamine- norepinephrine transporters delineote structural domains influencing selectivity for catecholamine and 1-methyl-4-phenylpyridinium. Proc Natl Acad Sci USA, 1994, 91 : 12584-12588.
  • 10Liu Y, Peter D, Roghani A, et al. A cDNA that suppresses MPP^+ toxicity encodes a vesicular amine transporter. Cell, 1992,70(4) : 539-551.

引证文献2

二级引证文献3

临床神经病学杂志
2008年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部